Canadian Market Suspends Sales of Adderall XR

The FDA has no plans to remove the drug that's been linked to 20 reports of sudden death in Canada.

Wednesday February 16th - 12:00am

On February 9, 2005, Canadian regulators suspended all sales of the long-acting stimulant medication Adderall XR. The decision was based on safety information released by the manufacturer, specifically, 20 reports of sudden deaths linked to the medication over the course of four years.

Currently, the FDA has no plans to remove the drug from the U.S. market, citing pre-existing conditions in some of the patients as well as the relative rarity of the deaths when compared to the 30 million prescriptions written within that time period. The FDA is deciding whether to conduct its own study of the drug, and will continue to closely monitor safety reports.

Stay turned for an in-depth look at the Adderall XR story in the next issue of ADDitude magazine.

<table align="center" cellpadding="10">

<td width="450" bgcolor="linen">

  • Please see the following links for additional information:

FDA statement on Adderall XR



Medical News Today

Copyright © 1998 - 2013 New Hope Media LLC. All rights reserved. Your use of this site is governed by our Terms of Service and Privacy Policy.
ADDitude does not provide medical advice, diagnosis, or treatment. The material on this web site is provided for educational purposes only. See additional information.
New Hope Media, 39 W. 37th Street, 15th Floor, New York, NY 10018